Sanofi and Regeneron Pharmaceuticals got effective results in reducing the risk of major adverse heart events in a clinical study of nearly 19,000 patients with the help of cholesterol drug Praluent. Drugmakers now hope that the results are good enough to convince insurers to pay for the pricey medicine. Treatment with Praluent was associated with fewer overall deaths, cutting down the risk of overall mortality by up to 15% as compared to the patients who received statin therapy. For improving the commercial scenario of the drug Sanofi and Regeneron showed willingness to reduce the net price of Praluent for certain high-risk patients only if U.S. payers agree to ease the restrictions that have so far limited access to the drug. Regeneron and Sanofi mentioned that they are planning to file a supplementary Biologics License Application to FDA by the mid of this year in hopes of adding the Odyssey data to Praluent’s label.
DelveInsight Blog
Related Article
iVEAcare’s $27.5 Million Series A Funding; AI Medical Service Joint Research Agreement with Mahidol University; CERENOVUS Launched Catheter; Cochlear FDA Clearance for The Osia System; Immunovia Announced Positive Results From The Model-Development Study; Hyalex Orthopaedics First Patients Treatment
iVEAcare Launched $27.5 Million Series A Funding from Leading Medtech Investors On April 24, 2024, iVEAcare, announced the closure of a $27.5 million Series A financing. The financing was led by Vensana Capital, which was joined by Treo Ventures, Hatteras Venture Partners, and an undisclosed strategic partner. i...
Find MoreIpsen and Skyhawk Therapeutics Partnership; SynOx Therapeutics’ Phase III Trial; Roche’s Alecensa FDA Approval; AbbVie’s RINVOQ Phase III SELECT-GCA Trial; AskBio’s AB-1002 FDA Fast Track Designation
Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the ...
Find MoreBaxter Introduced New Injectable Pharmaceuticals to US Market; Bayer and Hologic Collaborated to Deliver Contrast-Enhanced Mammography; Labcorp Received FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit; Onkos Surgical Won FDA De Novo Nod For Antibacterial-Coated Orthopedic Implants; Heartbeam Presented Positive Results On Its Artificial Intelligence Capabilities For Detecting Arrhythmias; Cognito Therapeutics Showed Positive Non-Invasive Neuromod Results
Baxter Introduced New Injectable Pharmaceuticals to US Market On April 11, 2024, the pharmaceutical portfolio of multinational medical goods corporation Baxter International Inc. was augmented with the introduction of five new injectable medications in the US market. The goods were made to fulfill essential dema...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2023
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.